Get the latest crypto news, updates, and reports by subscribing to our free newsletter.
Giấy phép số 4978/GP-TTĐT do Sở Thông tin và Truyền thông Hà Nội cấp ngày 14 tháng 10 năm 2019 / Giấy phép SĐ, BS GP ICP số 2107/GP-TTĐT do Sở TTTT Hà Nội cấp ngày 13/7/2022.
© 2026 Index.vn
REAL Shows Network (RSN) is a national TV network for top real estate professionals and influential local leaders, giving select hosts in each market the exclusive opportunity to lead a full 30-minute show showcasing their expertise, partners, and community. Created by an Emmy-nominated, Telly Award-winning production team, RSN delivers cinematic,…
Agenus Inc. (Nasdaq: AGEN) said data from an investigator-initiated Phase II trial conducted at Memorial Sloan Kettering Cancer Center will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 17–22, 2026, in San Diego, California. The study evaluates botensilimab (BOT) and balstilimab (BAL) in combination with agenT-797, an allogeneic iNKT cell therapy developed by MiNK Therapeutics, in patients with PD-1 refractory gastroesophageal cancer (GEC).
The presentation is scheduled for April 20, 2026, from 2:00–5:00 PM PT (5:00–8:00 PM EDT). The abstract is titled “A phase II study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in PD-1 refractory gastroesophageal cancer (GEC).”
Presenter: Samuel L. Cytyrn, MD, Gastrointestinal Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Session name: Phase II and Phase III Clinical Trials.
Poster section: 52.
Abstract number: CT166.
Botensilimab (BOT): A human Fc-enhanced multifunctional anti-CTLA-4 antibody designed to boost both innate and adaptive anti-tumor immune responses.
Balstilimab (BAL): A novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1.
agenT-797: An allogeneic iNKT cell therapy developed by MiNK Therapeutics, evaluated in combination with BOT and BAL in the trial.
The company said the study targets PD-1 refractory gastroesophageal cancer, an area of unmet need where resistance to checkpoint inhibition remains a major clinical challenge.
In brief\n\nBitcoin dropped to about $93,000, falling back below the EMA50 and putting its recent golden cross at risk of invalidation. The global crypto market cap stands at $3.15 trillion, down 2.38% in 24 hours. On Myriad Markets, 82% of the money is betting on Bitcoin pumping to $100K before…
